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Ectopy on a Single 12-Lead ECG, Incident Cardiac Myopathy, and
Death in the Community
Kaylin T. Nguyen, MD; Eric Vittinghoff, PhD; Thomas A. Dewland, MD; Jonathan W. Dukes, MD; Elsayed Z. Soliman, MD;
Phyllis K. Stein, PhD; John S. Gottdiener, MD; Alvaro Alonso, MD, PhD, MPH; Lin Y. Chen, MD, MS; Bruce M. Psaty, MD, PhD;
Susan R. Heckbert, MD, PhD; Gregory M. Marcus, MD, MAS
Background-—Atrial fibrillation and heart failure are 2 of the most common diseases, yet ready means to identify individuals at risk
are lacking. The 12-lead ECG is one of the most accessible tests in medicine. Our objective was to determine whether a premature
atrial contraction observed on a standard 12-lead ECG would predict atrial fibrillation and mortality and whether a premature
ventricular contraction would predict heart failure and mortality.
Methods and Results-—We utilized the CHS (Cardiovascular Health) Study, which followed 5577 participants for a median of
12 years, as the primary cohort. The ARIC (Atherosclerosis Risk in Communities Study), the replication cohort, captured data from
15 792 participants over a median of 22 years. In the CHS, multivariable analyses revealed that a baseline 12-lead ECG premature
atrial contraction predicted a 60% increased risk of atrial fibrillation (hazard ratio, 1.6; 95% CI, 1.3–2.0; P<0.001) and a premature
ventricular contraction predicted a 30% increased risk of heart failure (hazard ratio, 1.3; 95% CI, 1.0–1.6; P=0.021). In the negative
control analyses, neither predicted incident myocardial infarction. A premature atrial contraction was associated with a 30%
increased risk of death (hazard ratio, 1.3; 95% CI, 1.1–1.5; P=0.008) and a premature ventricular contraction was associated with a
20% increased risk of death (hazard ratio, 1.2; 95% CI, 1.0–1.3; P=0.044). Similarly statistically significant results for each analysis
were also observed in ARIC.
Conclusions-—Based on a single standard ECG, a premature atrial contraction predicted incident atrial fibrillation and death and a
premature ventricular contraction predicted incident heart failure and death, suggesting that this commonly used test may predict
future disease. ( J Am Heart Assoc. 2017;6:e006028. DOI: 10.1161/JAHA.117.006028.)
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A trial fibrillation (AF) and heart failure (HF) remain 2 of themost common cardiovascular diseases, each affecting
millions of individuals and contributing to significant morbidity
and mortality,1 yet available treatments remain suboptimal.1,2
Identification of high-risk groups and strategies to facilitate
primary prevention of AF and HF using widely accessible
methods are critical.3,4
Recent studies using wearable continuous Holter monitor-
ing have shown that frequent premature atrial contractions
(PACs) are associated with AF, stroke, and mortality.5,6
Similarly, frequent premature ventricular contractions (PVCs)
quantified by Holter studies are associated with incident HF
and mortality.7,8 Given evidence that successful ablation of
PACs can eradicate AF9 and that successful ablation of
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frequent PVCs can normalize systolic dysfunction,10,11
experts in the field now refer to ectopy as a cause of
myopathy.12–16
The standard 12-lead ECG is the most widely used cardiac
diagnostic test and is less expensive and burdensome for
patients than wearable recording devices. Previous studies
investigating the association between ectopic beats and
incident disease have relied on quantifying the number of
ectopic beats using long-term ECG monitoring.5–7,17 We
sought to investigate whether atrial or ventricular ectopy on
a single, standard 10-second 12-lead ECG is associated with
an increased risk of incident AF, HF, and mortality in 2 large,
prospective cohort studies.
Methods
We hypothesized that PACs are associated with incident AF
and that PVCs are associated with incident HF in 2
prospective cohort studies. For this study, based on current
literature and biological plausibility, “myopathy” was consid-
ered to manifest as AF in the atria and as HF in the ventricles
(and is meant to distinguish these clinically evident processes
from diseases of the vasculature, heart valves, conduction
system, or pericardium rather than to necessarily connote
grossly evident structural changes).
Cardiovascular Health Study (Primary Cohort)
Detailed methods describing the CHS (Cardiovascular Health
Study) have been previously published.18 Because previous
publications from this cohort have revealed the burden of
ectopy determined by continuously worn devices as predic-
tors of incident AF and HF in the CHS,5,7 we utilized the CHS
as the primary cohort. Briefly, the CHS is a prospective,
community-based cohort study to investigate risk factors for
stroke and coronary heart disease. Initially, from 1989 to
1990, 5201 adults aged 65 and older were recruited (original
cohort) from the Medicare eligibility lists from 4 US commu-
nities: Forsyth County (North Carolina), Sacramento County
(California), Washington County (Maryland), and Pittsburgh
(Pennsylvania). From 1992 to 1993, an additional 687 black
participants (new cohort) were recruited. Participants under-
went a comprehensive baseline assessment, including a
medical history, physical exam, laboratory testing, and resting
12-lead ECG. Prescription medication use was collected from
prescription bottles for any medication used within the past
2 weeks. Participants were followed semiannually with alter-
nating telephone calls and clinic visits until 1999, with resting
12-lead ECGs performed at every annual visit, after which
semiannual telephone contact was continued. During follow-
up through 2008, medical records were obtained for all
hospitalizations, and resting 12-lead ECGs were performed at
every annual visit through June 1999. Incident AF was
ascertained from annual resting ECGs, hospital discharge
diagnosis codes, and inpatient Medicare claims data. Incident
HF and myocardial infarction (MI) were identified through self-
report, hospital diagnosis codes, and inpatient and outpatient
medical records adjudicated by the CHS Cardiac Events
Subcommittee.19 Death was ascertained by reviewing medical
records, death certificates, autopsy exams, coroner’s reports,
obituaries, and search of the National Death Index.
ARIC (Replication Cohort)
Detailed methods regarding the ARIC (Atherosclerosis Risk in
Communities) Study have been previously published.20 ARIC
is a prospective, community-based cohort study to investigate
the etiology of atherosclerotic disease. Beginning in 1987,
15 792 adults aged 45 to 64 years were enrolled and
underwent a comprehensive medical history, physical exam-
ination, laboratory testing, ultrasound imaging, and resting 12-
lead ECG. Participants were selected by probability sampling
from 4 US communities: Forsyth County (North Carolina),
Jackson (Mississippi), the northwestern suburbs of Min-
neapolis (Minnesota), and Washington County (Maryland).
Only blacks were recruited at the Jackson location. Medica-
tion use was ascertained by self-reported use within the past
2 weeks and review of medication bottles. Participants were
contacted annually by telephone with repeated clinic visits
every 3 years until 1998 followed by a fifth visit from 2011 to
2013. During follow-up through 2011, incident AF was
identified from study visit ECGs, hospital discharge diagnosis,
and death certificates. Incident HF was diagnosed from
Clinical Perspective
What Is New?
• Among participants in 2 large, community-based cohort
studies, the presence of a premature atrial contraction
detected from a single, standard 12-lead ECG predicted a
statistically significant elevated risk of both incident atrial
fibrillation and death.
• Similarly, a premature ventricular contraction from a single,
standard ECG predicted statistically significant increased
risks of incident heart failure, decline in left ventricular
ejection fraction, and death.
What Are the Clinical Implications?
• In combination with other risk markers, ectopy on a single,
standard 12-lead ECG may provide valuable information
regarding an individual’s cardiovascular risk and serve as a
broadly available tool for the prediction and prevention of
atrial fibrillation, heart failure, and death.
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hospital discharge diagnosis codes and death certificates.
Incident MI was identified by self-report, hospital discharge
codes, discharge summaries, and evidence of MI on study
visit ECGs. Death was ascertained through annual follow-up,
hospital surveillance, and death registries and verified by
death certificate review.
For both studies: Participants provided written informed
consent and the study protocols were approved by the
institutional review board of each center.
ECG Assessment
In both studies, resting 10-second 12-lead ECGs were
recorded in a uniform fashion in all participants using MAC
PC ECG Machines (Marquette Electronics Inc, Milwaukee, WI).
ECG abnormalities were classified per the Minnesota Code.
We excluded participants with poor quality data, artificial
pacing, wandering atrial pacemaker, or missing ECG data
(n=298 in the CHS; n=263 in the ARIC).
Echocardiographic Evaluation
Echocardiographic assessment of participants in the CHS
has been described previously.21 In brief, at baseline, M-
mode, qualitative 2-dimensional echocardiography, and
Doppler imaging were acquired from each participant in
the original cohort recruited from 1989 to 1990. Measure-
ments were recorded by field technicians at each study
center on super-VHS tape using Toshiba SSH-160A
echocardiographic machines (Toshiba America, Tustin, CA)
equipped with 2.5- and 3.75-MHz transducers. Imaging was
performed at the highest MHz that provided adequate
tissue penetration for 2-dimensional imaging. Videotapes
were mailed weekly to the Echocardiography Reading
Center at the University of California, Irvine for interpreta-
tion. Left ventricular dysfunction was assessed from 2-
dimensional echocardiography using digitized images in
which at least 80% of the endocardium was visualized. The
average of 3 or more beats was utilized. Repeat echocar-
diograms were obtained 5 years after study entry. Quality
control measures included standardized training of staff,
assessment of inter-reader agreement (94%) and intrareader
agreement (92%) of paired studies, and quality-control
audits.22
Left ventricular ejection fractions (LVEFs) were subjectively
scored as normal, abnormal, or borderline. A decline in LVEF
was defined as a change on baseline echocardiogram of
“normal” or “borderline” to “moderate” or “severe” systolic
dysfunction on 5-year echocardiograms. HF was considered
to be associated with systolic dysfunction if the LVEF
assessed as part of that participant’s clinical care within
30 days of the event was <45%.
Statistical Analysis
Normally distributed continuous variables are presented as
meansSD and were compared using t tests, and continuous
variables with skewed distributions are presented as medians
and interquartile ranges and were compared using the
Wilcoxon rank-sum test. Categorical variables were compared
using the chi-squared test.
The primary predictors were the presence of at least 1 PAC
or at least 1 PVC on the baseline ECG. Statistically significant
associations found in the primary cohort (CHS) were exam-
ined in the replication cohort (ARIC). Visually confirmed
counts of PACs and PVCs were available in ARIC; we
examined the number of each in separate categories as
predictors of the primary outcomes as well as progressive
numbers of each to determine whether a “dose response”
was present. Participants with prevalent AF (n=177 in CHS;
n=33 in ARIC) were excluded from the incident AF analyses,
and those with prevalent HF (n=275 in CHS; n=730 in ARIC)
were excluded from the incident HF analyses. To adjust for
LVEF in CHS HF outcome analyses, those without baseline
echocardiography were excluded (n=736); a sensitivity anal-
ysis including all CHS participants was conducted and failed
to reveal any meaningful differences. In the ARIC study, PVC
and diabetes mellitus did not satisfy the proportional hazards
assumption; therefore, the hazard ratios (HRs) are reported
for the first 10 years of follow-up (comparable to length of
follow-up in the CHS) and the probability of incident HF was
graphed using an adjusted Kaplan–Meier curve. In the PVC-AF
model in the ARIC, we stratified by sex, race, and time-
dependent HF to meet the proportional hazards assumption.
Incident events were analyzed using Cox proportional
hazards models. Covariates were identified a priori based on
biological plausibility and previous literature and included: age,
sex, race (white/nonwhite), body mass index, hypertension,
diabetes mellitus, coronary disease, MI, and study center
(Table S1). Body mass index was dichotomized into normal
(<25 kg/m2) and abnormal (≥25 kg/m2) to meet model
linearity assumptions. Prevalent HF was included as a covariate
in the multivariable model examining AF as the outcome, and
AF, baseline LVEF (available in the CHS only), and beta-blocker
use were included in the HF outcome analysis. Plots for the
probability of incident AF and HF stratified by the presence or
absence of PACs or PVCs were based on multivariate Cox
models with covariates centered at their mean values. The
proportional hazards assumption was evaluated using the
Schoenfeld test and graphically (log-minus-log survival plots).
We evaluated the association between ectopy and incident
MI as a “negative control.” For these analyses, we excluded
individuals with prevalent MI (n=562 in the CHS) and adjusted
for age, sex, race, body mass index, hypertension, diabetes
mellitus, coronary disease, AF, and study center.
DOI: 10.1161/JAHA.117.006028 Journal of the American Heart Association 3
12-Lead Ectopy and Cardiac Myopathy and Death Nguyen et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
To examine whether ectopy of a given chamber (atrial
versus ventricular) led to a chamber-specific myopathy, we
examined whether PACs predicted HF and whether PVCs
predicted AF. We adjusted for time-dependent AF in the
multivariate Cox model evaluating the PAC-HF association and
for time-dependent HF in the PVC-AF model.
For mediation analyses (to determine how much ectopy-
associated mortality was statistically explained by interim AF
or HF), we calculated the “proportion of effect explained” as
the percentage reduction in the adjusted regression coeffi-
cient after additional adjustment for the candidate mediator,
with a 95% bias-corrected percentile bootstrap confidence
interval.
Data analyses were performed using Stata software
(version 14; StataCorp LP, College Station, TX). We consid-
ered a 2-tailed P<0.05 statistically significant.
Results
After exclusion criteria were applied in the CHS cohort, 5577
participants were available for the PAC-AF analyses and 4710
for the PVC-HF analyses. After exclusion criteria were applied
in the ARIC cohort, data from 15 132 participants were
available for the PAC-AF analyses and from 14 200 for the
PVC-HF analyses.
Baseline Characteristics and Premature Beats
At study entry, 234 participants (4.2%) had a PAC on their
standard baseline ECG in the CHS and 221 (1.5%) in the ARIC
study. Participants with a PAC were older and, in the CHS,
were more likely to be male and nonwhite compared with
those without a PAC (Table 1). At least 1 PVC was detected
on the standard ECG in 243 participants (5.2%) in the CHS
and 252 (1.8%) in the ARIC study. Participants with a PVC
were more likely to be older in both cohorts. In the CHS,
participants with at least 1 PVC were also more likely to be
male and have prevalent AF, whereas in ARIC they were more
likely to have a history of hypertension, coronary artery
disease, and MI.
A PAC on the Standard ECG and Incident AF
In CHS, 1534 participants (27.5%) developed AF during a median
follow-up of 12 years. In ARIC, 2059 participants (13.6%)
developed AF during a median follow-up of 22 years. The
presence of a PAC was associated with an 2-fold increased
risk of developing AF in the CHS (HR, 1.9; 95% CI, 1.5–2.4;
P<0.001); this relationshipwas attenuated toa60% increased risk
after multivariate adjustment (HR, 1.6; 95% CI, 1.3–2.0; P<0.001;
Figure 1). Similarly, in ARIC, a PAC was associated with greater
than a 2-fold increased risk of AF in both unadjusted (HR, 2.8; 95%
CI, 2.2–3.6; P<0.001) and adjusted (HR, 2.4; 95% CI, 1.9–3.1;
P<0.001; Figure 1) analyses. The association between a PAC and
AFwas comparable or greater inmagnitude towell-establishedAF
risk factors (Figure 2). In ARIC, where a PAC count on each 12-
lead ECG was available, no dose-response relationship was
observed between the number of 12-lead ECG PACs and AF risk
(Table 2).
A PVC on the Standard ECG and Incident HF
In the CHS cohort, 1391 participants (30%) developed HF,
and, in ARIC, 2449 participants (17%) developed HF. In
unadjusted analyses, the presence of a PVC on the standard
12-lead ECG was associated with an almost 2-fold elevated
risk of incident HF in CHS (HR, 1.8; 95% CI, 1.5–2.2;
P<0.001); after multivariable adjustment, there was a statis-
tically significant 30% increased risk of incident HF (CHS: HR,
1.3; 95% CI, 1.0–1.6; P=0.021). Similar findings were then
observed in the ARIC: A standard ECG PVC was associated
with a 3-fold increased risk before adjustment (HR, 3.1; 95%
CI, 2.2–4.3; P<0.001) and a 2-fold increased risk after
multivariable adjustment (HR, 2.0; 95% CI, 1.4–2.8; P<0.001;
Figure 2). In ARIC, where a PVC count on each 12-lead ECG
was available, no dose-response relationship was observed
between the number of 12-lead ECG PVCs and HF risk
(Table 2).
Of participants who developed HF in the CHS, 335 (24%)
events were associated with systolic dysfunction, 443 (22%) with
preserved systolic function, and 613 (44%) had an undetermined
assessment of systolic function. The presence of a PVC was
associated with incident HF with systolic dysfunction in both
unadjusted (HR, 2.8; 95% CI, 2.0–4.0; P<0.001) and adjusted
analyses (HR, 1.8; 95% CI, 1.2–2.5; P=0.003). However, a PVC
was not associated with incident HF with preserved systolic
function (unadjusted HR, 0.97; 95% CI, 0.57–1.6; P=0.01;
adjusted HR, 0.68; 95% CI, 0.38–1.2; P=0.19).
A PVC on the Standard ECG and
Echocardiographic Changes
Year 5 echocardiograms were available from 3102 CHS
participants (66%), 66 (2%) of whom had a reduction in LVEF.
Over 5 years, a PVC on the baseline ECG was associated with
an 3-fold greater odds of a reduction in LVEF in both
unadjusted (odds ratio, 3.4; 95% CI, 1.6–7.0; P=0.001) and
adjusted analyses (odds ratio, 2.8; 95% CI, 1.3–6.1; P=0.008).
Ectopy on the Standard ECG and Mortality
The presence of a PAC predicted death both in unadjusted
and adjusted analyses in both cohorts (Table 3). Interim AF
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mediated approximately more than one third of the PAC-
mortality relationship. A PVC on the ECG similarly predicted
mortality in both crude and multivariable analyses, again in
both cohorts (Table 3); interim HF statistically explained more
than half of the PVC-mortality relationship in the CHS and
20% of the association in ARIC.
Negative Control: Ectopy and Incident MI
To support the hypothesis that ectopy is associated with
myopathy rather than a nonspecific marker of cardiovascular
disease in general, we assessed the relationship between 12-
lead ECG ectopy and incident MI. In the CHS, neither PACs
(adjusted HR, 0.87; 95% CI, 0.61–1.3; P=0.45) nor PVCs
predicted incident MI (adjusted HR, 1.2; 95% CI, 0.93–1.6;
P=0.15).
Ectopy and “Cross-Chamber” Myopathy
To assess the chamber specificity of the ectopy-myopathy
relationship, we investigated whether a PAC predicted HF and
whether a PVC predicted AF. In the CHS, no statistically
significant association between a PAC and incident HF was
observed after multivariable adjustment (HR, 1.1; 95% CI,
0.87–1.5; P=0.36). However, the presence of a PVC was
associated with an increased risk of AF in CHS (HR, 1.3; 95%
CI, 1.1–1.6; P=0.007); this finding was replicated in ARIC (HR,
1.9; 95% CI, 1.2–3.0; P=0.005).
Figure 1. Probability of incident outcomes by the presence of ectopy on the baseline standard ECG. Ectopy was defined as the presence of at
least 1 PAC (in the AF analysis) and at least 1 PVC (in the HF analysis). Models were adjusted for age, sex, race, hypertension, diabetes mellitus,
myocardial infarction, coronary artery disease, body mass index, study center, and heart failure (in AF outcome analyses) and AF, baseline left
ventricular ejection fraction, and beta-blocker use (in heart failure outcome analyses). AF indicates atrial fibrillation; ARIC, Atherosclerosis Risk
in Communities study; CHS, Cardiovascular Health Study; HF, heart failure; PAC, premature atrial contraction; PVC, premature ventricular
contraction.
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Discussion
In 2 large, prospective, community-based cohorts, a single
ECG with at least 1 PAC was associated with an increased risk
of incident AF and death and at least 1 PVC predicted an
increased risk of incident HF, a significant decline in LVEF,
and death. Each was associated with a substantially increased
risk of death, which, in both cases, appeared to be mediated,
in large part, by the incident myopathy. We found no evidence
of a dose-response relationship between the number of
ectopic beats and the outcomes studied, and even a single
PAC predicted AF and a single PVC presaged subsequent HF.
AF is themost common sustained arrhythmia.1 Because of the
lack of clear preventive strategies, increasing prevalence, and
high morbidity and mortality associated with AF,1,23 there is
increasing interest in identifying clinically accessible and modi-
fiable risk factors.3 PACs have been shown to be critical to AF
pathogenesis and AF ablation is built on the premise that triggers
or PACs arising in pulmonary veins initiate AF, suggesting that
PACsmaybeamodifiable risk factor forAF inparticular subsets of
patients.9,24 In addition, the presence of ectopy of the 12-lead
ECG may identify patients in clinical practice who would benefit
from further studies, such as with continuous Holter monitoring,
to further assess the burden of ectopy.
Even if no causal relationship between PACs and AF exists
in many patients, the ability to identify PACs may yet be
important for prediction.5 Specifically, useful predictors may
help identify the best candidates for preventive therapies,
and/or identify patients who will benefit the most from more-
careful monitoring (such as with continuous or implantable
monitors) to determine appropriate candidacy for stroke
prevention using anticoagulation.2,25 If a causal relationship
between either PACs and AF or PVCs and HF does indeed
exist, ultimately these findings may also help inform trials
investigating prophylactic interventions, such as catheter
ablation, to prevent AF and/or HF or pharmacological therapy,
such as with beta-blockers, to prevent systolic dysfunction.
In addition to demonstrating replication in our replication
analyses, our findings are consistent with previous literature
describing a different population: In a secondary analysis of
an important recent study of over 60 000 Japanese individ-
uals participating in annual health exams, Murakoshi et al
demonstrated a greater risk of AF in those with a supraven-
tricular premature contraction on baseline, standard resting
12-lead ECG.26 These findings complement ours well. Addi-
tionally, our analyses benefit from a longer length of follow-up
(11.7 and 22.4 years compared to 5.8 years), more-thorough
incident AF ascertainment and ascertainment of covariates, a
Figure 2. Multivariate-adjusted hazard ratios for the association between baseline characteristics and incident outcomes. Models were
adjusted for study center and atrial fibrillation (in HF analyses) and baseline ejection fraction (in HF analyses in CHS) in addition to the listed
covariates. *For every 10-year increase in age. †Risk in individuals with abnormal BMI (≥25 kg/m2) compared to normal (<25 kg/m2). Error
bars represent 95% CI. ARIC indicates Atherosclerosis Risk in Communities study; BMI, body mass index; CAD, coronary artery disease; CHS,
Cardiovascular Health Study; HF, heart failure; MI, myocardial infarction; PAC, premature atrial contraction; PVC, premature ventricular
contraction.
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more-diverse population, and mediation analyses related to
mortality.
Consistent with our hypothesis that ventricular ectopy
would predict ventricular myopathy, we demonstrated that,
after adjustment for potential confounders, ventricular ectopy
on a single ECG was associated with a 30% to 100% increased
risk of HF and a decline in LVEF. Given that its prevalence
increases with an aging population, HF is quickly becoming a
major public health burden, making its prevention as well as
the identification of reversible causes and high-risk groups
important priorities.4
The HF events associated with the presence of 1 or more
PVCs appears to be predominantly associated with systolic
dysfunction. This is consistent with studies from multiple
cardiac electrophysiology groups demonstrating that success-
ful ablation of frequent PVCs can improve, and even
normalize, reduced ejection fractions among patients with
severe systolic dysfunction.10,11,27
Table 2. Number of 12-Lead ECG Ectopic Beats as a Predictor of Outcomes in ARIC
Risk of Incident Atrial Fibrillation
Number of PACs on the
Baseline 12-Lead ECG
Unadjusted Analyses Multivariable Adjusted Analyses*
HR 95% CI P Value HR 95% CI P Value
1 2.8 2.2 to 3.6 <0.001 2.5 1.9 to 3.2 <0.001
2 2.4 1.3 to 4.3 0.004 1.8 1.0 to 3.2 0.075
>3 3.6 2.3 to 5.7 <0.001 3.0 1.9 to 4.8 <0.001
Risk of Incident Heart Failure
Number of PVCs on the
Baseline 12-Lead ECG
Unadjusted Analyses Multivariable Adjusted Analyses†
HR 95% CI P Value HR 95% CI P Value
1 2.5 2.0 to 3.1 <0.001 1.8 1.5 to 2.3 <0.001
2 2.3 1.5 to 3.6 <0.001 1.6 1.0 to 2.5 0.032
>3 2.6 1.8 to 3.7 <0.001 2.0 1.4 to 2.9 <0.001
HR indicates hazard ratio; PAC, premature atrial contraction; PVC, premature ventricular contraction.
*Adjusted for age, sex, race, body mass index, hypertension, diabetes mellitus, myocardial infarction, coronary artery disease, heart failure, and study site.
†Adjusted for age, sex, race, body mass index, hypertension, diabetes mellitus, myocardial infarction, coronary artery disease, atrial fibrillation, and study site.
Table 3. Baseline 12-Lead ECG Ectopy and Overall Mortality
Adjustment
CHS ARIC
Point Estimate 95% CI P Value Point Estimate 95% CI P Value
A 12-lead PAC as a predictor of mortality
None HR 1.6 1.4 to 1.9 <0.001 HR 1.8 1.5 to 2.1 <0.001
* HR 1.3 1.1 to 1.5 0.008 HR 1.4 1.2 to 1.7 <0.001
Plus* interim AF HR 1.2 1.0 to 1.4 0.08 HR 1.2 1.0 to 1.5 0.06
% mediated by AF 35% 0.2% to 124% 42% 16% to 111%
A 12-lead PVC as a predictor of mortality
None HR 1.5 1.3 to 1.7 <0.001 HR 2.3 1.9 to 2.7 <0.001
† HR 1.2 1.0 to 1.3 0.044 HR 1.7 1.4 to 2.0 <0.001
Plus† interim HF HR 1.1 0.9 to 1.2 0.42 HR 1.5 1.3 to 1.8 <0.001
% mediated by HF 60% 5% to 709% 22% 0% to 45%
White shaded areas include results regarding ectopy as a predictor of mortality. Gray shaded areas include mediation results (specifically how much the PAC-mortality relationship is
attenuated and therefore statistically explained by interim atrial fibrillation and how much the PVC-mortality relationship is attenuated and therefore statistically explained by interim heart
failure). AF indicates atrial fibrillation; ARIC, Atherosclerosis Risk in Communities; CHS, Cardiovascular Health Study; HF, heart failure; HR, hazard ratio; PAC, premature atrial contraction;
PVC, premature ventricular contraction.
*Adjusted for age, sex, race, study site, hypertension, diabetes mellitus, myocardial infarction, coronary artery disease, heart failure, and study site.
†Adjusted for age, sex, race, study site, hypertension, diabetes mellitus, myocardial infarction, coronary artery disease, beta-blocker, atrial fibrillation, and study site (in CHS, also adjusted
for baseline left ventricular ejection fraction).
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Because 10-second 12-lead ECGs are nearly ubiquitous in
clinical research studies and clinical practice and are
remarkably superior tools to localize and characterize specific
ectopic beats, we believe that the current findings substan-
tially broaden opportunities for secondary analyses of pre-
existing data sets and ultimately for clinical practice in ways
not feasible when considering Holter or other continuous
monitoring data. The purpose of the current research is to
enhance awareness of these readily accessible predictors,
which can be used to investigate various prevention
approaches, to study effect modification of different treat-
ments efficacies (including by retrospective studies), and be
considered by clinicians in their practice to identify patients
who may benefit from additional monitoring (such as with
Holter monitoring). As with PACs and AF, the importance of
the relationship between PVCs and HF does not rely on
causality. Even if simply a marker of future risk, some patients
with PVCs may benefit from more-frequent monitoring (such
as with serial echocardiograms), or preventative therapies (eg,
with beta-blockers or radiofrequency ablation).28 However,
additional research studies are needed to provide compara-
tive outcomes in patients treated with these strategies.
Consistent with our hypothesis, neither PACs nor PVCs
predicted incident MI, suggesting that ectopy is not simply a
nonspecific marker of future adverse cardiovascular events in
general. A PAC on a single, standard ECG failed to predict HF,
suggesting that PACs predict outcomes specific to the atria.
Of interest, however, a PVC predicted incident AF even after
adjusting for HF that occurred in the interim. The mechanism
underlying this observation remains unknown, but, if causal,
may be related to repeated atrioventricular dyssynchrony or, if
not causal, may represent a general propensity to cardiac
arrhythmias.29
Importantly, a PAC on the standard 12-lead ECG predicted
overall mortality in both cohorts. Whereas this observation is
consistent with previous data using Holter monitoring,5,7 it
underscores the impact that ectopy on a standard ECG might
deliver. Of interest, much of the relationship between a PAC
and subsequent death appeared to be mediated by incident
AF. Similarly, a single, standard ECG-detected PVC was
associated with increased mortality, also explained, at least in
part, by incident HF.
Our study has several limitations. Our study was not
designed to compare the strength of effects between different
risk factors or their prognostic values for our outcomes of
interest. In addition, it is likely that ectopic beats are clinically
meaningful predictors of disease for only a subset of patients
who develop AF or HF. Our participants were at least 45 years
old, and thus these findings may not be generalizable to
younger populations. Echocardiograms were not performed at
the baseline visit in the ARIC study; therefore, we cannot
exclude residual confounding from undetected left ventricular
dysfunction in the replication cohort. Importantly, however,
whereas this might help elucidate mechanism and causality, it
would not negate the ability of a PVC to predict HF events. We
also recognize that the term “myopathy” may not be optimal
in describing AF, which itself may not require structural
changes; we chose this term to provide common language for
both AF and HF and primarily to distinguish from other types
of heart disease (such as coronary or valve disease, for
example). Finally, although PACs have been shown to initiate
AF and PVCs have been found to cause heart failure,9,11 our
study was not designed to prove causality. However, the
absence of causality would not negate neither the validity nor
the potential importance of the ability of these 12-lead-
derived ectopic beats to predict each of our incident
outcomes.
Conclusions
In 2 prospective, community-based cohort studies, the
presence of at least 1 PAC on a standard 12-lead ECG was
an important predictor of incident AF and at least 1 PVC was
an important predictor of incident HF and a decline in LVEF.
Either ECG finding alone predicted mortality, which was, at
least partly, explained by the interim myopathy. Our findings
suggest that even a single ectopic beat might provide valuable
information regarding a patient’s future. The vast numbers of
ECGs already collected in previous research and the avail-
ability of this common test should facilitate the identification
of optimal approaches to leverage these observations to
enhance risk stratification and prevention strategies for AF
and HF. Future studies are needed to characterize PAC and
PVC morphology and coupling intervals to assess whether
certain types of PACs or PVCs are responsible for the
associations found, assess the use of 12-lead ectopy to risk
stratify patients and identify patients who may have improved
outcomes with additional monitoring, and assess causality
and/or the potential benefit of treatment of ectopic beats.
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SUPPLEMENTAL MATERIAL 
Table S1. Definitions of baseline co-morbidities used in multivariate models 
Cardiovascular Health Study Atherosclerosis Risk in Communities Study 
Hypertension Reported history of hypertension with 
the use of antihypertensive 
medication, systolic blood pressure of 
≥140 mmHg, or diastolic pressure of 
≥90 mmHg on baseline exam 
Antihypertensive medication use, systolic 
blood pressure of ≥140 mmHg, or 
diastolic pressure of ≥90 mmHg on 
baseline exam 
Diabetes Use of antihyperglycemic medication 
or a fasting glucose concentration 
≥126 mg/dL 
Self-reported physician-diagnosed 
diabetes, use of antihyperglycemic 
medication, fasting blood glucose ≥126 
mg/dL or random blood glucose ≥200 
mg/dL 
Coronary heart disease Self-reported angina or previous 
coronary artery bypass, angioplasty, or 
myocardial infarction with 
confirmation by medical record 
review 
Self-reported history of coronary artery 
bypass, angioplasty, or myocardial 
infarction 
Myocardial infarction (MI) Self-reported with medical record 
verification 
Self-reported history of physician-
diagnosed MI or previous MI evident on 
baseline 12-lead ECG 
Congestive heart failure Self-reported with the use of 
medication (both diuretics and either 
digitalis or a vasodilator) or confirmed 
by medical record review 
Heart failure medication use or clinical 
evidence of heart failure 
Atrial fibrillation (AF) Self-reported at baseline, AF on 
baseline Holter monitoring or on 
baseline standard ECG 
Evidence of AF on baseline ECG 
